N

    Nexgel Inc (NXGL)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $0.36
    +0.01 (+1.93%)

    Market Cap: $3.43M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    25%(5/20)
    Avg Surprise
    -150.88%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.24
    Range$-0.24 - $-0.24
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.04+83.3%
    60d ago$-0.04+83.3%
    30d ago$-0.04+83.3%
    7d ago$-0.04+83.3%
    Current$-0.24
    Revenue Consensus
    $4M
    Range$4M - $4M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.51
    Range$-0.51 - $-0.51
    1 analysts
    Revenue Consensus
    $3M
    Range$3M - $3M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.51---
    Sep 26EST
    		-$-0.24---
    Jun 26
    Reported Aug 11
    		$-0.40$-0.12-233.33%Miss-300.0%
    Mar 26
    Reported May 13
    		$-0.11$-0.07-57.14%Miss-22.2%
    Dec 25
    Reported Mar 31
    		$-0.15$-0.03-396.00%Miss-35.3%
    Sep 25
    Reported Nov 11
    		$-0.08$-0.08+0.00%Beat+27.3%
    Jun 25
    Reported Aug 12
    		$-0.10$-0.07-42.86%Miss+33.3%
    Mar 25
    Reported May 13
    		$-0.09$-0.10+10.00%Beat+35.7%
    Dec 24
    Reported Mar 24
    		$-0.11$-0.10-10.00%Miss+47.6%
    Sep 24
    Reported Nov 13
    		$-0.11$-0.10-10.00%Miss+0.0%
    Jun 24
    Reported Aug 19
    		$-0.15$-0.14-7.14%Miss-7.1%
    Mar 24
    Reported Apr 1
    		$-0.14$-0.18+22.22%Beat+12.5%
    Dec 23
    Reported Mar 18
    		$-0.21$-0.11-90.91%Miss-90.9%
    Sep 23
    Reported Nov 13
    		$-0.11$-0.12+8.33%Beat+47.6%
    Jun 23
    Reported Aug 14
    		$-0.14$-0.13-7.69%Miss+26.3%
    Mar 23
    Reported May 15
    		$-0.16$-0.14-14.29%Miss+42.9%
    Dec 22
    Reported Mar 27
    		$-0.11$-0.15+26.67%Beat+78.8%
    Sep 22
    Reported Nov 8
    		$-0.21$-0.13-61.54%Miss+0.0%
    Jun 22
    Reported Aug 10
    		$-0.19$-0.15-26.67%Miss-26.7%
    Mar 22
    Reported May 12
    		$-0.28$-0.15-86.67%Miss-115.4%
    Dec 21
    Reported Mar 21
    		$-0.52$-0.37-40.54%Miss-
    Sep 21
    Reported Nov 10
    		$-0.21$-0.01-2000.00%Miss-
    Jun 21
    Reported Aug 16
    		$-0.15$0.00N/AMiss-
    Mar 21
    Reported May 17
    		$-0.13$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.49EV/EBITDA-0.85x
    Price/FCF-0.97xFCF Yield-103.22%
    Profitability
    Profit Margin-51.30%Operating Margin-68.00%
    ROE-115.10%ROIC-35.07%
    Financial Health
    Debt/Equity0.73xInterest CoverageN/A
    Current Ratio0.43xQuick Ratio0.27x
    Trading Statistics
    Beta0.77Avg Volume1.68M
    52-Week High$2.8952-Week Low$0.30

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.37
    SMA 20$0.39
    SMA 50$0.45
    SMA 200$0.94
    EMA 10$0.37
    EMA 20$0.39
    EMA 50$0.45
    EMA 200$0.95

    MACD

    Line: -0.03Signal: -0.03Hist: -0.00

    ADX

    ADX: 20.7+DI: 17.8-DI: 27.5

    Aroon & PSAR

    Aroon Up56.0
    Aroon Down80.0
    PSAR$0.51

    Bollinger Bands

    Upper Band$0.50
    Lower Band$0.28
    %B Position5609%(Upper)
    Band Width0.35

    RSI (14-Day)

    Neutral
    44.2

    Momentum Oscillators

    Stoch %K18.4
    Stoch %D18.4
    Williams %R-79.8
    ROC (10d)-4.4%
    Momentum-0.02
    CCI (20d)-70.8
    MFI (14d)88.9

    Volatility Measures

    ATR (14d)$0.06(15.5%)
    StdDev (20d)0.06
    Hist Vol201.8%(High)

    Volume Flow

    VWAP$0.35
    OBV23.1M
    AD Line23.1M
    CMF (20d)0.724

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio0.1x(Low)
    VWMA (20d)$0.39

    Pivot Points

    R3$0.39
    R2$0.37
    R1$0.36
    Pivot Point$0.35
    S1$0.34
    S2$0.32
    S3$0.31

    Advanced Oscillators

    TSI-11.69
    Ultimate Osc52.0
    KST-162.03

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$3.69M$2.65M$2.80M$2.93M$2.88M$2.81M$3.04M$2.94M$1.44M$1.27M$1.08M$1.22M
    Cost of Revenue$2.58M$1.59M$1.98M$1.69M$1.63M$1.62M$1.90M$1.78M$1.15M$1.11M$1.17M$877,000
    Gross Profit$1.11M$1.06M$820,000$1.24M$1.26M$1.19M$1.14M$1.16M$293,000$160,000$-88,000$344,000
    Operating Expenses$3.61M$2.02M$2.03M$1.97M$1.89M$1.97M$2.00M$1.94M$1.35M$1.03M$1.13M$956,000
    R&D$20,000$0$-6,000$7,000$0$1,000$0$0$76,000$2,000$13,000$6,000
    SG&A$3.59M$2.02M$2.04M$1.96M$1.89M$1.96M$1.98M$1.94M$1.27M$1.03M$1.12M$950,000
    Operating Income$-2,505,000$-958,000$-1,214,000$-725,000$-636,000$-777,000$-841,000$-788,000$-1,054,000$-871,000$-1,220,000$-612,000
    Interest Income$-2,226,000$-42,000$0$10,000$-21,000$-21,000$0$-20,000$-29,000$-15,000$0$45,000
    Interest Expense$1.10M$0$0$0$4,000$0$0$0$0$34,000$2,000$3,000
    Income Before Tax$-3,606,000$-871,000$-928,000$-647,000$-640,000$-678,000$-825,000$-754,000$-979,000$-905,000$-1,187,000$-552,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,606,000$-871,000$-928,000$-647,000$-640,000$-678,000$-825,000$-754,000$-979,000$-905,000$-1,187,000$-552,000
    EBITDA$1.50M$-646,000$-814,000$-544,000$-450,000$-485,000$-682,000$-550,000$-868,000$-821,000$-899,000$-559,000
    EBIT$-1,380,000$-829,000$-926,000$-657,000$-619,000$-657,000$-790,000$-734,000$-950,000$-890,000$-1,022,000$-594,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NXGL

    News

    NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

    NEXGEL announced positive results from a randomized single-center IRB study evaluating its hydrogel laser treatment patch for laser hair removal. The study found a 95.6% reduction in plume concentration, significantly decreasing laser plume generation and exposure. Additionally, the patch was associated with greater hair reduction and reduced pain compared to a control group.

    Barchart.com•8/28/26•
    Neutral

    NXGL Downgraded by Maxim Group -- Rating Changed to Hold

    Maxim Group has downgraded NexGel (NXGL) to Hold from Buy, with analyst Naz Rahman revising the price target from $6.00 to $2.00, reflecting a significant shift in sentiment. While GuruFocus's GF Value suggests NXGL is 92.2% undervalued, its moderate GF Score of 60/100, coupled with low financial strength and valuation ratings, and insider selling activity, signals caution for investors. The company specializes in medical devices and instruments, but is currently unprofitable and cash-flow negative.

    GuruFocus•8/24/26•
    Bearish

    NEXGEL (NXGL) terminates CEO and launches broad strategic review

    NEXGEL (NXGL) has terminated its CEO, Adam R. Levy, effective August 21, 2026, and appointed Brian Kieser as Interim CEO. The company's Board has formed a Special Committee for Strategic Review and Value Creation to assess operations, asset portfolio, liquidity, and long-term strategic direction, with an initial framework expected within 30 to 45 days. This move aims to strengthen operational execution, improve liquidity, and enhance long-term shareholder value.

    Stock Titan•8/21/26•
    Somewhat-Bearish

    NEXGEL Names Brian Kieser Interim CEO, Launches Strategic Review

    NEXGEL, Inc. has appointed Brian Kieser as interim chief executive officer, effective August 21, 2026, succeeding Adam Levy. Concurrently, the company has formed a Special Committee for Strategic Review and Value Creation, tasked with improving liquidity, simplifying operations, and evaluating non-core assets. This move follows NEXGEL's acquisition of certain assets from Celularity, Inc. four months prior, with Kieser having already been involved in the integration of the BioNX Surgical division.

    citybiz•8/21/26•
    Neutral

    NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE

    NEXGEL, Inc. (NASDAQ: NXGL) announced a leadership transition and a strategic review initiative to strengthen operations, improve liquidity, and enhance shareholder value. Brian Kieser has been appointed Interim Chief Executive Officer, and a Special Committee for Strategic Review and Value Creation has been formed to evaluate strategic alternatives, capital structure, and operational efficiency. Former CEO Adam Levy will cease serving as CEO and employee, providing transition assistance for 90 days.

    GlobeNewswire•8/20/26•
    Somewhat-Bullish

    Frequently Asked Questions About NXGL

    Does NXGL pay dividends?
    Nexgel Inc (NXGL) does not currently pay a regular dividend.
    What is NXGL's market cap?
    Nexgel Inc (NXGL) has a market capitalization of $3.43M with a current stock price of $0.36.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In